| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥67.2B | ¥64.6B | +3.9% |
| Operating Income | ¥3.2B | ¥5.3B | -38.5% |
| Ordinary Income | ¥3.6B | ¥5.5B | -34.0% |
| Net Income | ¥2.3B | ¥3.9B | -40.7% |
| ROE | 9.2% | 17.6% | - |
FY2025 results show a divergent performance with revenue reaching ¥67.2B (YoY +3.9%), while profitability deteriorated significantly. Operating income declined to ¥3.2B (YoY -38.5%), ordinary income fell to ¥3.6B (YoY -34.0%), and net income dropped to ¥2.3B (YoY -40.7%). The company maintained positive revenue momentum but faced substantial margin compression, with operating margin declining to 4.8% from approximately 8.2% in the prior year. Despite the profit decline, operating cash flow remained healthy at ¥4.0B (YoY +58.5%), indicating solid cash generation capability. The company invested heavily in capital expenditures of ¥4.4B, resulting in negative free cash flow of ¥0.6B, suggesting an active growth investment phase. Management forecasts a strong recovery for the full year with revenue of ¥75.3B (YoY +12.2%) and operating income of ¥6.2B (YoY +90.3%), indicating expectations for investment payback and operational improvement.
Revenue grew ¥2.6B or 3.9% YoY to ¥67.2B, driven by top-line expansion across the business. However, this modest revenue growth failed to translate into profit growth due to deteriorating cost structure. Gross profit decreased to ¥13.0B with gross margin of 19.3%, representing a decline from prior year levels. Cost of sales increased to ¥54.2B, consuming 80.7% of revenue and compressing the gross profit margin. SG&A expenses rose to ¥9.7B, representing 14.5% of revenue, which combined with the lower gross profit led to operating income declining ¥2.1B or 38.5% to ¥3.2B. The operating margin compression from approximately 8.2% to 4.8% indicates significant operational leverage challenges.
Non-operating income contributed ¥0.5B, primarily from dividend income of ¥0.1B, while non-operating expenses were limited to ¥0.1B in interest payments. This resulted in ordinary income of ¥3.6B, down 34.0% YoY. The gap between operating and ordinary income of ¥0.4B represents 12.5% of operating income, driven by positive net non-operating factors. Extraordinary losses of ¥0.2B, including ¥0.2B in disposal losses and ¥0.1B in litigation settlement costs, represented non-recurring factors impacting the bottom line. After income tax expense of ¥1.1B (effective tax rate 31.6%), net income settled at ¥2.3B, down 40.7% YoY. This represents a revenue up/profit down pattern, where top-line growth was more than offset by margin compression and cost structure deterioration, resulting in significant bottom-line contraction despite revenue expansion.
[Profitability] ROE of 9.2% demonstrates moderate return on equity, with the decline primarily attributable to net profit margin compression. Operating margin contracted sharply to 4.8% from the prior year's approximately 8.2%, driven by gross margin deterioration to 19.3% and SG&A expense ratio of 14.5%. The DuPont analysis reveals ROE composition of 3.5% net profit margin, 1.643 asset turnover, and 1.60 financial leverage, with profit margin decline being the dominant factor in ROE compression. Basic EPS decreased 40.4% to ¥167.65 from ¥281.41, while diluted EPS was ¥165.96. [Cash Quality] Cash and deposits stood at ¥7.3B, providing 0.70 coverage of short-term liabilities. Operating cash flow of ¥4.0B represented 1.71 times net income, indicating strong cash conversion. The cash conversion rate of 1.02 and accruals ratio of -4.1% confirm high earnings quality with profits backed by actual cash generation. [Investment Efficiency] Asset turnover of 1.643 reflects efficient revenue generation relative to asset base. Days sales outstanding of 65 days indicates collection cycle extending beyond the 60-day threshold, warranting attention to receivables management. The company executed significant capital investments with CapEx of ¥4.4B, representing 6.5% of revenue, alongside investment securities increasing 40.5% to ¥5.1B. [Financial Health] Equity ratio of 62.4% reflects conservative capital structure with strong solvency. Current ratio of 191.3% and identical quick ratio indicate robust short-term liquidity. Long-term debt of ¥3.1B results in debt-to-equity ratio of 0.12, with Debt/EBITDA of 0.78 suggesting manageable leverage. Interest coverage approximates 45 times based on interest expense of ¥0.1B, indicating comfortable debt service capacity.
Operating cash flow of ¥4.0B represents 1.71 times net income, confirming cash-backed earnings quality despite profit decline. The operating CF subtotal before working capital changes was ¥5.6B, with depreciation and amortization of ¥0.7B adding back to profits. Working capital movements included inventory increase of ¥0.1B and payables decrease of ¥0.2B, while income taxes paid consumed ¥1.5B. Interest and dividends received contributed ¥0.1B while interest paid was minimal at ¥0.1B. Investing cash flow of -¥4.6B was dominated by capital expenditures of ¥4.4B, representing substantial investment in property, plant and equipment that drove the 40.0% increase in tangible fixed assets. This resulted in negative free cash flow of ¥0.6B, indicating the company is in an active investment phase prioritizing growth over immediate cash returns. Financing cash flow of ¥0.3B reflected modest share repurchases of ¥0.3B, demonstrating disciplined capital allocation. The combination of strong operating cash generation and heavy investment activity positions the company for future growth, though near-term free cash flow remains pressured by capital deployment.
Ordinary income of ¥3.6B versus operating income of ¥3.2B shows positive non-operating net contribution of approximately ¥0.4B, representing 12.5% of operating income. Non-operating income of ¥0.5B comprises primarily dividend income of ¥0.1B from investment securities holdings, reflecting the company's portfolio of financial assets. Non-operating expenses were limited to ¥0.1B in interest costs, resulting in favorable net non-operating contribution. Non-operating income represents 0.7% of revenue, indicating modest reliance on non-core activities. Extraordinary losses of ¥0.2B including asset disposal losses and litigation settlement represent non-recurring factors that reduced pre-tax income. Operating cash flow of ¥4.0B exceeded net income of ¥2.3B by 71%, with the operating CF to net income ratio of 1.71 indicating healthy earnings quality. The accruals ratio of -4.1% confirms that earnings are well-supported by cash flow rather than accounting accruals, while the cash conversion rate of 1.02 demonstrates effective translation of profits into cash. These metrics collectively indicate that despite the profit decline, the underlying earnings quality remains high with strong cash generation characteristics.
Current period performance shows revenue achievement of 89.2% versus full-year guidance of ¥75.3B, and operating income achievement of 52.4% versus full-year guidance of ¥6.2B. With standard annual progress rates of 50% at the half-year mark, revenue tracking is above plan while operating income is slightly ahead of schedule, suggesting conservative initial guidance or back-loaded profit expectations. The company forecasts full-year revenue of ¥75.3B (YoY +12.2%), operating income of ¥6.2B (YoY +90.3%), ordinary income of ¥6.6B (YoY +81.6%), and net income of ¥4.4B (YoY +89.0%). The substantial profit recovery guidance implies operating margin expansion to approximately 8.2% from the current 4.8%, requiring significant improvement in cost structure and operational efficiency. This represents an aggressive turnaround from current profitability levels, suggesting that management expects the benefits from the ¥4.4B capital investment program to materialize in the second half, alongside improvements in gross margin and operating leverage. The forecast implies second-half operating income of approximately ¥3.0B compared to first-half ¥3.2B, indicating expectations for sustained profitability improvement. Achievement will depend on successful implementation of margin enhancement initiatives and realization of investment returns.
The company maintained a zero dividend policy for the period with no interim or year-end dividends declared. The reported payout ratio of 62.6% in the data appears inconsistent with the actual zero dividend distribution, as the forecast shows ¥0.00 dividend per share. The company executed share repurchases of ¥0.3B during the period, representing minimal capital return activity. With net income of ¥2.3B and zero dividends paid, the effective payout ratio is 0%, indicating a policy of full earnings retention for internal investment and growth. This approach aligns with the substantial capital investment program evidenced by ¥4.4B in CapEx and the 40.5% increase in investment securities. The combination of zero dividends and modest buybacks results in a total shareholder return ratio near zero, reflecting management's prioritization of growth investment over immediate cash returns to shareholders. The retained earnings increased ¥2.2B or 15.4% to ¥16.6B, demonstrating accumulation of internal capital. Given the negative free cash flow of ¥0.6B driven by investment activities, the current dividend policy appears sustainable and appropriate, allowing the company to fund growth initiatives from operating cash flow. Future dividend resumption would likely depend on completion of the investment phase and restoration of positive free cash flow generation.
Profitability deterioration represents the primary risk, with operating margin compressing from approximately 8.2% to 4.8% and net income declining 40.7% despite revenue growth of 3.9%. The gross margin decline to 19.3% and SG&A expense ratio of 14.5% indicate structural cost challenges requiring operational improvements. If the company cannot reverse margin compression through pricing power, cost reduction, or investment returns, sustained profitability pressure may continue.
Accounts receivable collection extending to 65 days sales outstanding exceeds the 60-day monitoring threshold and represents working capital efficiency risk. Trade receivables of ¥12.0B constitute 17.9% of revenue, and prolonged collection cycles could strain cash flow and increase credit risk exposure. Deterioration in customer payment patterns or concentration in slow-paying clients could further impact liquidity despite currently adequate cash position.
Capital investment returns and execution risk emerge from the substantial ¥4.4B CapEx program that increased tangible fixed assets by 40.0% and generated negative free cash flow of ¥0.6B. The company's ability to achieve the forecasted 90.3% operating income recovery depends heavily on successful deployment and monetization of these investments. Delays in project completion, lower-than-expected returns, or market demand shortfalls could impair the investment recovery and extend the period of depressed profitability and negative free cash flow.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial metrics show mixed positioning relative to industry standards. Operating margin of 4.8% indicates below-average operational efficiency, representing a significant decline from prior year levels and suggesting competitive or cost structure challenges. The net profit margin of 3.5% similarly reflects compressed profitability that warrants operational improvement focus. ROE of 9.2% demonstrates moderate equity returns, though the decline from prior periods indicates profitability headwinds. The equity ratio of 62.4% reflects conservative financial management with above-average solvency, positioning the company as financially stable relative to peers. Revenue growth of 3.9% represents steady but modest expansion, while the substantial capital investment program of ¥4.4B suggests active pursuit of future growth opportunities. The combination of strong balance sheet metrics and challenged profitability indicators suggests a company in transition, prioritizing strategic investment over near-term margins. The negative free cash flow position driven by growth investments distinguishes the company as being in an investment phase rather than cash harvesting mode, requiring assessment of investment return realization timeline.
※ Benchmarks based on proprietary analysis of comparable publicly traded companies. Individual company positioning may vary based on business model and strategic priorities.
The earnings data reveals a company executing a significant investment-driven transformation while facing near-term profitability challenges. Operating cash flow of ¥4.0B exceeding net income by 71% demonstrates underlying cash generation strength despite the 40.7% decline in reported profits, indicating that the earnings deterioration stems from operational margin compression rather than cash flow quality issues. The substantial capital investment program of ¥4.4B, representing a 40.0% increase in tangible fixed assets, positions the company for potential future growth but creates near-term pressure with negative free cash flow of ¥0.6B.
The operating margin contraction from approximately 8.2% to 4.8% represents a critical inflection point requiring reversal through either revenue leverage, cost structure improvement, or investment returns. Management's aggressive full-year guidance projecting 90.3% operating income recovery implies confidence in second-half improvement, though achievement depends on successful execution of margin enhancement initiatives and investment monetization. The conservative capital structure with 62.4% equity ratio and minimal leverage provides financial flexibility to sustain the investment phase, while the zero dividend policy appropriately prioritizes capital retention for growth funding.
Working capital management emerges as an area requiring attention, with days sales outstanding of 65 days indicating collection cycle extension that could constrain cash flow efficiency. The company's ability to improve receivables turnover while converting capital investments into profitable revenue growth will determine whether the current investment phase successfully drives long-term value creation or extends the period of depressed profitability. The forecast period will serve as a critical test of whether strategic investments generate anticipated returns and restore margin expansion.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.